MedTrace Logo

Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate

NCT01666041 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-11-04

No results posted yet for this study

Summary

The investigators hypothesize that fenofibrate/omega will improve insulin resistance compared with fenofibrate

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

placebo

DRUG

fenofibrate/omega

DRUG

fenofibrate

Sponsors & Collaborators

  • Gachon University Gil Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-02-28
Completion
2013-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01666041 on ClinicalTrials.gov